CH
VRTX icon

Canton Hathaway’s Vertex Pharmaceuticals VRTX Stock Holding History

Canton Hathaway’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Hold
62
– – 0.01% 245
2026
Q1 		$27.7K Hold
62
– – 0.01% 238
2025
Q4 		$28.1K Hold
62
– – 0.01% 245
2025
Q3 		$24K Hold
62
– – ﹤0.01% 258
2025
Q2 		$28K Hold
62
– – 0.01% 244
2025
Q1 		$30K Hold
62
– – 0.01% 238
2024
Q4 		$25K Hold
62
– – 0.01% 222
2024
Q3 		$29K Hold
62
– – 0.01% 213
2024
Q2 		$29K Hold
62
– – 0.01% 207
2024
Q1 		$26K Hold
62
– – 0.01% 218
2023
Q4 		$25K Hold
62
– – 0.01% 212
2023
Q3 		$22K Hold
62
– – 0.01% 216
2023
Q2 		$22K Buy
+62
New +$20.9K 0.01% 221

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Canton Hathaway's VRTX Position: Q2 2026 in Review

Canton Hathaway held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 62 shares worth $30.8K. The position accounts for 0.01% of the portfolio, ranked #245.

Canton Hathaway first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Canton Hathaway held 62 shares of Vertex Pharmaceuticals worth $30.8K as of Q2 2026.
  • Canton Hathaway left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Canton Hathaway's portfolio in Q2 2026, its #245 holding.
  • Canton Hathaway first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.